Detalhe da pesquisa
1.
RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer.
Breast Cancer Res
; 23(1): 42, 2021 03 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-33785053
2.
Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer.
Breast Cancer Res
; 21(1): 79, 2019 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31277676
3.
Trafficking and localisation to the plasma membrane of Nav 1.5 promoted by the ß2 subunit is defective due to a ß2 mutation associated with Brugada syndrome.
Biol Cell
; 109(7): 273-291, 2017 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-28597987
4.
Targeting Breast Cancer Stem Cells to Overcome Treatment Resistance.
Molecules
; 23(9)2018 Aug 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-30200262
5.
(-)-Epigallocatechin 3-Gallate Synthetic Analogues Inhibit Fatty Acid Synthase and Show Anticancer Activity in Triple Negative Breast Cancer.
Molecules
; 23(5)2018 May 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29751678
6.
Breast Cancer Stem Cell Culture and Enrichment Using Poly(ε-Caprolactone) Scaffolds.
Molecules
; 21(4): 537, 2016 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-27120585
7.
Polycaprolactone Electrospun Scaffolds Produce an Enrichment of Lung Cancer Stem Cells in Sensitive and Resistant EGFRm Lung Adenocarcinoma.
Cancers (Basel)
; 13(21)2021 Oct 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34771484
8.
Fatty Acid Synthase Inhibitor G28 Shows Anticancer Activity in EGFR Tyrosine Kinase Inhibitor Resistant Lung Adenocarcinoma Models.
Cancers (Basel)
; 12(5)2020 May 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-32438613
9.
Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer.
Clin Cancer Res
; 22(18): 4687-97, 2016 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27106068
10.
Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs.
PLoS One
; 10(6): e0131241, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26107737